Regulatory Filing Details

Initiative Details

Wockhardt has launched the "Wockhardt Antibiotic Academy," described as an initiative for patient-centric scientific dialogue to tackle multidrug resistance. The academy is positioned as an open scientific learning platform accessible to registered medical professionals across India.

Purpose and Rationale

The initiative aims to address antimicrobial resistance (AMR), which is described as "one of the greatest threats to global public healthcare." The disclosure states that approximately 10 lakh patients die annually in India due to multi-drug-resistant infections, which is more than four times the number of Indian lives lost annually during the COVID-19 pandemic.

Academy Objectives

  • Facilitate continuous medical education through knowledge exchange
  • Enable scientific discussions among healthcare professionals
  • Share real-world clinical experience
  • Promote evidence-based solutions for antimicrobial resistance management
  • Create deeper understanding of current drug resistance realities

Leadership Commentary

Dr. Habil Khorakiwala, Founder Chairman: Emphasized the need for both new antibiotics like Zaynich and a science-based platform for dialogue on AMR. Stated essentiality of using "the right antibiotic for the right patient at the right time."

Dr. Subramaniam Swaminathan, President Clinical Infectious Diseases Society, India: Highlighted that resistance is solved at the patient's bedside through clinical decisions that improve when physicians learn from one another.

Ms. Annapurna Das, President, India & NCE Emerging Markets: Noted that every breakthrough antibiotic is only the beginning, with true value emerging through robust evidence and clinical judgment.

Company Background

Wockhardt is described as a research-based global pharmaceutical and biotech company with:

  • Approximately 3,200 employees across 27 nationalities
  • Presence in UK, Ireland, Switzerland, France, Mexico, Russia and other countries
  • Manufacturing and research facilities in India and UK
  • Manufacturing facility in Ireland
  • 78% of global revenues coming from international businesses

Drug Discovery Program

Wockhardt's New Drug Discovery programme focuses on unmet needs for antibacterial drugs effective against "untreatable superbugs." The company has received QIDP Status (Qualified Infectious Disease Product) from USFDA for 6 antibacterial discovery programmes - 3 Gram Negative and 3 Gram Positive effective against untreatable "Superbugs."

Financial Impact

Financial impact not quantified in the disclosure. The initiative appears to be an educational and scientific platform rather than a direct revenue-generating activity.